“Neuropathic Ocular Pain Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuropathic Ocular Pain Market.
The Neuropathic Ocular Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Neuropathic Ocular Pain Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Neuropathic Ocular Pain treatment therapies with a considerable amount of success over the years. Neuropathic Ocular Pain Key players such as - Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum Biotechnologies and MeiraGTx, Ocular Therapeutix, Aldeyra Therapeutics, and others, are developing therapies for the Neuropathic Ocular Pain treatment
-
Neuropathic Ocular Pain Emerging therapies such as - Lidocaine, Ketamine, Nerve stimulation, Gene Therapy, Gabapentin, Pregabalin, and others are expected to have a significant impact on the Neuropathic Ocular Pain market in the coming years.
-
In October 2024, OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP)—a condition with no FDA-approved treatment—announced the commencement of patient screening and recruitment for a Phase 2 trial of OK-101 to treat NCP. This double-masked, randomized, 12-week placebo-controlled trial will involve 48 patients with NCP, confirmed through confocal microscopy. The study's primary goal is to assess pain relief using the Visual Analog Scale (VAS).
-
Horizon Therapeutics plc received FDA approval in 2021 for TEPEZZA (teprotumumab-trbw) for the treatment of thyroid eye disease, which is characterized by inflammation and swelling in the eye. While not specifically indicated for neuropathic ocular pain, TEPEZZA may offer relief for some patients with ocular pain that is caused by inflammation and swelling.
-
Alcon Inc. (a subsidiary of Novartis International AG) received FDA approval in 2021 for PATADAY Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution) 0.7% for the treatment of ocular itching associated with allergic conjunctivitis. While not specifically indicated for neuropathic ocular pain, PATADAY may offer relief for some patients with ocular pain that is caused by itching and inflammation.
Neuropathic Ocular Pain Overview
Neuropathic ocular pain (NOP), also referred to as corneal neuropathic pain, is a condition in which corneal pain is seen in response to normally non-painful stimuli. This pain results from repeated direct damage to corneal nerves.
Get a Free Sample PDF Report to know more about Neuropathic Ocular Pain Pipeline Therapeutic Assessment-
Neuropathic Ocular Pain Pipeline Therapeutics Assessment
-
Neuropathic Ocular Pain Assessment by Product Type
-
Neuropathic Ocular Pain By Stage and Product Type
-
Neuropathic Ocular Pain Assessment by Route of Administration
-
Neuropathic Ocular Pain By Stage and Route of Administration
-
Neuropathic Ocular Pain Assessment by Molecule Type
-
Neuropathic Ocular Pain by Stage and Molecule Type
DelveInsight's Neuropathic Ocular Pain Report covers around products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Download Sample PDF Report to know more about Neuropathic Ocular Pain drugs and therapies
Some of the key companies in the Neuropathic Ocular Pain Therapeutics Market include:
Key Companies developing therapies for Neuropathic Ocular Pain treatment are - Allergan (a subsidiary of AbbVie Inc.), Bausch Health Companies Inc., Johnson & Johnson Vision Care, Inc., Novartis International AG, Ocular Therapeutix, Inc., Shire (a subsidiary of Takeda Pharmaceutical Company Limited), Santen Pharmaceutical Co., Ltd., Akorn, Inc., Horizon Therapeutics plc, Alcon Inc. (a subsidiary of Novartis International AG), and others.
Emerging Neuropathic Ocular Pain Drugs Under Different Phases of Clinical Development Include:
-
Lidocaine: Aciex Therapeutics
-
Ketamine: Novaliq
-
Nerve stimulation: Oculeve and Allergan
-
Gene Therapy: Adverum Biotechnologies and MeiraGTx
-
Gabapentin: Ocular Therapeutix
-
Pregabalin: Aldeyra Therapeutics
Further Neuropathic Ocular Pain product details are provided in the report. Download the Neuropathic Ocular Pain pipeline report to learn more about the emerging Neuropathic Ocular Pain therapies
Neuropathic Ocular Pain Pipeline Analysis:
The Neuropathic Ocular Pain pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Neuropathic Ocular Pain with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuropathic Ocular Pain Treatment.
-
Neuropathic Ocular Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Neuropathic Ocular Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuropathic Ocular Pain market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Scope of Neuropathic Ocular Pain Pipeline Drug Insight
-
Coverage: Global
-
Key Neuropathic Ocular Pain Companies: Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum Biotechnologies and MeiraGTx, Ocular Therapeutix, Aldeyra Therapeutics, and others
-
Key Neuropathic Ocular Pain Therapies: Lidocaine, Ketamine, Nerve stimulation, Gene Therapy, Gabapentin, Pregabalin, and others
-
Neuropathic Ocular Pain Therapeutic Assessment: Neuropathic Ocular Pain current marketed and Neuropathic Ocular Pain emerging therapies
-
Neuropathic Ocular Pain Market Dynamics: Neuropathic Ocular Pain market drivers and Neuropathic Ocular Pain market barriers
Request for Sample PDF Report for Neuropathic Ocular Pain Pipeline Assessment and clinical trials
Table of Contents
| 1 | Neuropathic Ocular Pain Report Introduction |
| 2 | Neuropathic Ocular Pain Executive Summary |
| 3 | Neuropathic Ocular Pain Overview |
| 4 | Neuropathic Ocular Pain- Analytical Perspective In-depth Commercial Assessment |
| 5 | Neuropathic Ocular Pain Pipeline Therapeutics |
| 6 | Neuropathic Ocular Pain Late Stage Products (Phase II/III) |
| 7 | Neuropathic Ocular Pain Mid Stage Products (Phase II) |
| 8 | Neuropathic Ocular Pain Early Stage Products (Phase I) |
| 9 | Neuropathic Ocular Pain Preclinical Stage Products |
| 10 | Neuropathic Ocular Pain Therapeutics Assessment |
| 11 | Neuropathic Ocular Pain Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Neuropathic Ocular Pain Key Companies |
| 14 | Neuropathic Ocular Pain Key Products |
| 15 | Neuropathic Ocular Pain Unmet Needs |
| 16 | Neuropathic Ocular Pain Market Drivers and Barriers |
| 17 | Neuropathic Ocular Pain Future Perspectives and Conclusion |
| 18 | Neuropathic Ocular Pain Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
